P47 REAL-WORLD DATA OF ATTRITION RATES BY SUBSEQUENT LINES OF THERAPY IN MULTIPLE MYELOMA PATIENTS TREATED IN A TERTIARY CARE ITALIAN CENTRE

por Morè, S., Offidani, M., Corvatta, L., Manieri, V.M., Olivieri, A.
Publicado 2023

P25: CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS

por Morè, S, Manieri, V M, Corvatta, L, Morsia, E, Rupoli, S, Olivieri, A, Offidani, M
Publicado 2022

PB2024: PREVALENCE OF TYPE 1 GAUCHER DISEASE IN PATIENTS WITH MULTIPLE MYELOMA: FIRST INTERIM ANALYSIS OF A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY

por Offidani, M., Zizzo, C., Rupoli, S., Federici, I., Bossi, A., Morè, S., Manieri, V. M., Petrucci, M. T., Caravita di Toritto, T., Brunori, M., Gozzetti, A., Tordi, A., Fazio, F., Lisi, C., Morsia, E., Corvatta, L., Olivieri, A., Duro, G.
Publicado 2022

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study

por Offidani, M, Corvatta, L, Maracci, L, Liberati, A M, Ballanti, S, Attolico, I, Caraffa, P, Alesiani, F, Caravita di Toritto, T, Gentili, S, Tosi, P, Brunori, M, Derudas, D, Ledda, A, Gozzetti, A, Cellini, C, Malerba, L, Mele, A, Andriani, A, Galimberti, S, Mondello, P, Pulini, S, Coppetelli, U, Fraticelli, P, Olivieri, A, Leoni, P
Publicado 2013